

Gastric Cancer Drugs Market by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2023-2028

<https://marketpublishers.com/r/GFC96025090CEN.html>

Date: January 2023

Pages: 143

Price: US\$ 2,499.00 (Single User License)

ID: GFC96025090CEN

Abstracts

The global gastric cancer drugs market size reached US\$ 4.11 Billion in 2022. Looking forward, IMARC Group expects the market to reach US\$ 8.93 Billion by 2028, exhibiting a growth rate (CAGR) of 12.9% during 2023-2028. The rising prevalence of chronic and acute indications, growing incidences of weight-related health concerns, and increasing health consciousness represent some of the key factors driving the market.

Gastric cancer drugs are medications developed to relieve or treat an individual diagnosed with stomach cancer in which malignant cells form in the lining of the stomach. Some common symptoms of gastric cancer are unexplained weight loss, indigestion, bloating, nausea, vomiting, heartburn, and difficulty swallowing food. Doxorubicin hydrochloride, sunitinib, mitomycin, fluorouracil, imatinib, and docetaxel are commonly available gastric cancer drugs. They help to shrink a tumor and relieve signs and symptoms of cancer by killing some of the cancer cells. They also assist in reducing cancer cells from growing, dividing, and making more cells. As a result, gastric cancer drugs are administered through oral and parenteral forms and are used by hospitals, clinics, and special treatment centers.

The increasing geriatric population and the rising prevalence of obesity across the globe are primarily driving the market growth. In line with this, the growing incidences of weight-related health concerns due to unhealthy eating habits and sedentary lifestyles are favoring the market growth. Moreover, the increasing cases of cancer, due to the rising consumption of tobacco-based products and alcoholic beverages, and the

enhanced need need for preventive and therapeutic medications are acting as another growth-inducing factor. Apart from this, the introduction of two gastric cancer biomarkers that help in eliminating tumor growth is providing an impetus to the market growth. Moreover, manufacturers are focusing on creating product variants with minimal side effects, such as gastric erosion and nausea, thus propelling the market toward growth. Along with this, rapid technological advancements focusing on the development of effective and specific cancer treatments are creating a positive outlook for the market. Furthermore, leading pharmaceutical companies and key players are investing heavily in research and development (R&D) activities to develop gastric cancer drugs that are safer, more effective, economically viable, and easier to administer. Besides this, the implementation of various government initiatives to promote the manufacturing, processing, and packing of a drug product ensuring the quality of drugs produced by manufacturers is positively influencing the market growth. Other factors, including rising healthcare expenditure and growing consumer awareness regarding the symptoms and the available treatment options for gastric cancer, are anticipated to drive the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global gastric cancer drugs market, along with forecasts at the global, regional, and country level from 2023-2028. Our report has categorized the market based on type, route of administration and end user.

Type Insights

Doxorubicin Hydrochloride

Sunitinib

Docetaxel

Mitomycin

Fluorouracil

Imatinib

Trastuzumab

The report has provided a detailed breakup and analysis of the gastric cancer drugs market based on the type. This includes doxorubicin hydrochloride, sunitinib, docetaxel, mitomycin, fluorouracil, imatinib, and trastuzumab. According to the report, trastuzumab represented the largest segment.

Route of Administration Insights

Oral

Parenteral

A detailed breakup and analysis of the gastric cancer drugs market based on the route of administration has also been provided in the report. This includes oral and parenteral. According to the report, parenteral accounted for the largest market share.

End User Insights

Hospitals

Clinics

Others

The report has also provided a detailed breakup and analysis of the gastric cancer drugs market based on the end user. This includes hospitals, clinics, and others. According to the report, hospitals represented the largest segment.

Regional Insights

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, Asia Pacific was the largest market for gastric cancer drugs. Some of the factors driving the Asia Pacific gastric cancer drugs market included its high healthcare expenditure, technological advancements, and rising geriatric population.

Competitive Landscape

The report has also provided a comprehensive analysis of the competitive landscape in the global gastric cancer drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Arog Pharmaceuticals Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, Ono Pharmaceutical Co. Ltd., Sanofi S.A., Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.), etc. Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

How has the global gastric cancer drugs market performed so far and how will it perform in the coming years?

What are the drivers, restraints, and opportunities in the global gastric cancer drugs market?

What are the key regional markets?

Which countries represent the most attractive gastric cancer drugs market?

What is the breakup of the market based on the type?

What is the breakup of the market based on the route of administration?

What is the breakup of the market based on end user?

What is the competitive structure of the global gastric cancer drugs market?

Who are the key players/companies in the global gastric cancer drugs market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 INTRODUCTION

- 4.1 Overview
- 4.2 Key Industry Trends

5 GLOBAL GASTRIC CANCER DRUGS MARKET

- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast

6 MARKET BREAKUP BY TYPE

- 6.1 Doxorubicin Hydrochloride
 - 6.1.1 Market Trends
 - 6.1.2 Market Forecast
- 6.2 Sunitinib
 - 6.2.1 Market Trends
 - 6.2.2 Market Forecast
- 6.3 Docetaxel

- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Mitomycin
 - 6.4.1 Market Trends
 - 6.4.2 Market Forecast
- 6.5 Fluorouracil
 - 6.5.1 Market Trends
 - 6.5.2 Market Forecast
- 6.6 Imatinib
 - 6.6.1 Market Trends
 - 6.6.2 Market Forecast
- 6.7 Trastuzumab
 - 6.7.1 Market Trends
 - 6.7.2 Market Forecast

7 MARKET BREAKUP BY ROUTE OF ADMINISTRATION

- 7.1 Oral
 - 7.1.1 Market Trends
 - 7.1.2 Market Forecast
- 7.2 Parenteral
 - 7.2.1 Market Trends
 - 7.2.2 Market Forecast

8 MARKET BREAKUP BY END USER

- 8.1 Hospitals
 - 8.1.1 Market Trends
 - 8.1.2 Market Forecast
- 8.2 Clinics
 - 8.2.1 Market Trends
 - 8.2.2 Market Forecast
- 8.3 Others
 - 8.3.1 Market Trends
 - 8.3.2 Market Forecast

9 MARKET BREAKUP BY REGION

- 9.1 North America

- 9.1.1 United States
 - 9.1.1.1 Market Trends
 - 9.1.1.2 Market Forecast
- 9.1.2 Canada
 - 9.1.2.1 Market Trends
 - 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
 - 9.2.1 China
 - 9.2.1.1 Market Trends
 - 9.2.1.2 Market Forecast
 - 9.2.2 Japan
 - 9.2.2.1 Market Trends
 - 9.2.2.2 Market Forecast
 - 9.2.3 India
 - 9.2.3.1 Market Trends
 - 9.2.3.2 Market Forecast
 - 9.2.4 South Korea
 - 9.2.4.1 Market Trends
 - 9.2.4.2 Market Forecast
 - 9.2.5 Australia
 - 9.2.5.1 Market Trends
 - 9.2.5.2 Market Forecast
 - 9.2.6 Indonesia
 - 9.2.6.1 Market Trends
 - 9.2.6.2 Market Forecast
 - 9.2.7 Others
 - 9.2.7.1 Market Trends
 - 9.2.7.2 Market Forecast
- 9.3 Europe
 - 9.3.1 Germany
 - 9.3.1.1 Market Trends
 - 9.3.1.2 Market Forecast
 - 9.3.2 France
 - 9.3.2.1 Market Trends
 - 9.3.2.2 Market Forecast
 - 9.3.3 United Kingdom
 - 9.3.3.1 Market Trends
 - 9.3.3.2 Market Forecast
 - 9.3.4 Italy

- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
 - 9.3.5.1 Market Trends
 - 9.3.5.2 Market Forecast
- 9.3.6 Russia
 - 9.3.6.1 Market Trends
 - 9.3.6.2 Market Forecast
- 9.3.7 Others
 - 9.3.7.1 Market Trends
 - 9.3.7.2 Market Forecast
- 9.4 Latin America
 - 9.4.1 Brazil
 - 9.4.1.1 Market Trends
 - 9.4.1.2 Market Forecast
 - 9.4.2 Mexico
 - 9.4.2.1 Market Trends
 - 9.4.2.2 Market Forecast
 - 9.4.3 Others
 - 9.4.3.1 Market Trends
 - 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
 - 9.5.1 Market Trends
 - 9.5.2 Market Breakup by Country
 - 9.5.3 Market Forecast

10 DRIVERS, RESTRAINTS, AND OPPORTUNITIES

- 10.1 Overview
- 10.2 Drivers
- 10.3 Restraints
- 10.4 Opportunities

11 VALUE CHAIN ANALYSIS

12 PORTERS FIVE FORCES ANALYSIS

- 12.1 Overview
- 12.2 Bargaining Power of Buyers

12.3 Bargaining Power of Suppliers

12.4 Degree of Competition

12.5 Threat of New Entrants

12.6 Threat of Substitutes

13 PRICE ANALYSIS

14 COMPETITIVE LANDSCAPE

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

14.3.1 Abbott Laboratories

14.3.1.1 Company Overview

14.3.1.2 Product Portfolio

14.3.1.3 Financials

14.3.1.4 SWOT Analysis

14.3.2 Arog Pharamaceuticals Inc.

14.3.2.1 Company Overview

14.3.2.2 Product Portfolio

14.3.3 Bristol-Myers Squibb Company

14.3.3.1 Company Overview

14.3.3.2 Product Portfolio

14.3.3.3 Financials

14.3.3.4 SWOT Analysis

14.3.4 Daiichi Sankyo Company Limited

14.3.4.1 Company Overview

14.3.4.2 Product Portfolio

14.3.4.3 Financials

14.3.4.4 SWOT Analysis

14.3.5 Eli Lilly and company

14.3.5.1 Company Overview

14.3.5.2 Product Portfolio

14.3.5.3 Financials

14.3.5.4 SWOT Analysis

14.3.6 F. Hoffmann-La Roche AG

14.3.6.1 Company Overview

14.3.6.2 Product Portfolio

14.3.6.3 Financials

14.3.7 Ono Pharmaceutical Co. Ltd.

14.3.7.1 Company Overview

14.3.7.2 Product Portfolio

14.3.7.3 Financials

14.3.7.4 SWOT Analysis

14.3.8 Sanofi S.A.

14.3.8.1 Company Overview

14.3.8.2 Product Portfolio

14.3.8.3 Financials

14.3.8.4 SWOT Analysis

14.3.9 Taiho Pharmaceutical Co. Ltd. (Otsuka Pharmaceutical Co. Ltd.)

14.3.9.1 Company Overview

14.3.9.2 Product Portfolio

14.3.9.3 SWOT Analysis

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report

List Of Tables

LIST OF TABLES

Table 1: Global: Gastric Cancer Drugs Market: Key Industry Highlights, 2022 & 2028

Table 2: Global: Gastric Cancer Drugs Market Forecast: Breakup by Type (in Million US\$), 2023-2028

Table 3: Global: Gastric Cancer Drugs Market Forecast: Breakup by Route of Administration (in Million US\$), 2023-2028

Table 4: Global: Gastric Cancer Drugs Market Forecast: Breakup by End User (in Million US\$), 2023-2028

Table 5: Global: Gastric Cancer Drugs Market Forecast: Breakup by Region (in Million US\$), 2023-2028

Table 6: Global: Gastric Cancer Drugs Market: Competitive Structure

Table 7: Global: Gastric Cancer Drugs Market: Key Players

List Of Figures

LIST OF FIGURES

- Figure 1: Global: Gastric Cancer Drugs Market: Major Drivers and Challenges
- Figure 2: Global: Gastric Cancer Drugs Market: Sales Value (in Billion US\$), 2017-2022
- Figure 3: Global: Gastric Cancer Drugs Market Forecast: Sales Value (in Billion US\$), 2023-2028
- Figure 4: Global: Gastric Cancer Drugs Market: Breakup by Type (in %), 2022
- Figure 5: Global: Gastric Cancer Drugs Market: Breakup by Route of Administration (in %), 2022
- Figure 6: Global: Gastric Cancer Drugs Market: Breakup by End User (in %), 2022
- Figure 7: Global: Gastric Cancer Drugs Market: Breakup by Region (in %), 2022
- Figure 8: Global: Gastric Cancer Drugs (Doxorubicin Hydrochloride) Market: Sales Value (in Million US\$), 2017 & 2022
- Figure 9: Global: Gastric Cancer Drugs (Doxorubicin Hydrochloride) Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 10: Global: Gastric Cancer Drugs (Sunitinib) Market: Sales Value (in Million US\$), 2017 & 2022
- Figure 11: Global: Gastric Cancer Drugs (Sunitinib) Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 12: Global: Gastric Cancer Drugs (Docetaxel) Market: Sales Value (in Million US\$), 2017 & 2022
- Figure 13: Global: Gastric Cancer Drugs (Docetaxel) Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 14: Global: Gastric Cancer Drugs (Mitomycin) Market: Sales Value (in Million US\$), 2017 & 2022
- Figure 15: Global: Gastric Cancer Drugs (Mitomycin) Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 16: Global: Gastric Cancer Drugs (Fluorouracil) Market: Sales Value (in Million US\$), 2017 & 2022
- Figure 17: Global: Gastric Cancer Drugs (Fluorouracil) Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 18: Global: Gastric Cancer Drugs (Imatinib) Market: Sales Value (in Million US\$), 2017 & 2022
- Figure 19: Global: Gastric Cancer Drugs (Imatinib) Market Forecast: Sales Value (in Million US\$), 2023-2028
- Figure 20: Global: Gastric Cancer Drugs (Trastuzumab) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 21: Global: Gastric Cancer Drugs (Trastuzumab) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 22: Global: Gastric Cancer Drugs (Oral) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 23: Global: Gastric Cancer Drugs (Oral) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 24: Global: Gastric Cancer Drugs (Parenteral) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 25: Global: Gastric Cancer Drugs (Parenteral) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 26: Global: Gastric Cancer Drugs (Hospitals) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 27: Global: Gastric Cancer Drugs (Hospitals) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 28: Global: Gastric Cancer Drugs (Clinics) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 29: Global: Gastric Cancer Drugs (Clinics) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 30: Global: Gastric Cancer Drugs (Other End Users) Market: Sales Value (in Million US\$), 2017 & 2022

Figure 31: Global: Gastric Cancer Drugs (Other End Users) Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 32: North America: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 33: North America: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 34: United States: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 35: United States: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 36: Canada: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 37: Canada: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 38: Asia-Pacific: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 39: Asia-Pacific: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 40: China: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 &

2022

Figure 41: China: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 42: Japan: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 43: Japan: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 44: India: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 45: India: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 46: South Korea: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 47: South Korea: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 48: Australia: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 49: Australia: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 50: Indonesia: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 51: Indonesia: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 52: Others: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 53: Others: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 54: Europe: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 55: Europe: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 56: Germany: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 57: Germany: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 58: France: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 59: France: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 60: United Kingdom: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 61: United Kingdom: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 62: Italy: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 63: Italy: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 64: Spain: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 65: Spain: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 66: Russia: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 67: Russia: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 68: Others: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 69: Others: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 70: Latin America: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 71: Latin America: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 72: Brazil: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 73: Brazil: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 74: Mexico: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 75: Mexico: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 76: Others: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 77: Others: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 78: Middle East and Africa: Gastric Cancer Drugs Market: Sales Value (in Million US\$), 2017 & 2022

Figure 79: Middle East and Africa: Gastric Cancer Drugs Market: Breakup by Country

(in %), 2022

Figure 80: Middle East and Africa: Gastric Cancer Drugs Market Forecast: Sales Value (in Million US\$), 2023-2028

Figure 81: Global: Gastric Cancer Drugs Industry: Drivers, Restraints, and Opportunities

Figure 82: Global: Gastric Cancer Drugs Industry: Value Chain Analysis

Figure 83: Global: Gastric Cancer Drugs Industry: Porter's Five Forces Analysis

I would like to order

Product name: Gastric Cancer Drugs Market by Type (Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab), Route of Administration (Oral, Parenteral), End User (Hospitals, Clinics, and Others), and Region 2023-2028

Product link: <https://marketpublishers.com/r/GFC96025090CEN.html>

Price: US\$ 2,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GFC96025090CEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970